Equities analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to announce earnings of ($0.12) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.14). ZIOPHARM Oncology reported earnings of ($0.13) per share in the same quarter last year, which suggests a positive year over year growth rate of 7.7%. The company is expected to issue its next earnings report on Monday, November 5th.
On average, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.50) per share for the current fiscal year, with EPS estimates ranging from ($0.55) to ($0.42). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.50) to ($0.22). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.12) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.12).
Several analysts recently commented on the stock. BidaskClub cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Tuesday, June 26th. JPMorgan Chase & Co. cut shares of ZIOPHARM Oncology from a “neutral” rating to an “underweight” rating in a research note on Monday, June 18th. ValuEngine upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.50 price objective on shares of ZIOPHARM Oncology in a research note on Monday, May 14th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.25.
Shares of NASDAQ ZIOP traded down $0.06 during midday trading on Monday, hitting $2.66. The company had a trading volume of 810,382 shares, compared to its average volume of 908,105. ZIOPHARM Oncology has a twelve month low of $2.23 and a twelve month high of $6.60. The stock has a market capitalization of $387.27 million, a price-to-earnings ratio of -5.02 and a beta of 1.39.
Institutional investors and hedge funds have recently made changes to their positions in the business. Summit Trail Advisors LLC raised its position in ZIOPHARM Oncology by 351.7% during the first quarter. Summit Trail Advisors LLC now owns 125,392 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 97,632 shares during the last quarter. Raymond James & Associates raised its position in ZIOPHARM Oncology by 168.3% during the second quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 36,568 shares during the last quarter. MetLife Investment Advisors LLC raised its position in ZIOPHARM Oncology by 77.1% during the second quarter. MetLife Investment Advisors LLC now owns 65,990 shares of the biotechnology company’s stock worth $199,000 after acquiring an additional 28,734 shares during the last quarter. Chessman Wealth Strategies RIA acquired a new position in ZIOPHARM Oncology during the second quarter worth about $218,000. Finally, Bank of America Corp DE raised its position in shares of ZIOPHARM Oncology by 198.1% in the second quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock valued at $301,000 after buying an additional 201,063 shares during the last quarter. Institutional investors own 39.29% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Featured Story: What kind of dividend yield to CEF’s pay?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.